11C-5-HTP PET in Clinical Islet Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In people with type I diabetes, the insulin producing cells in the pancreas have been destroyed. Presently one can only evaluate the function of the graft through laboratory tests, blood sugars and the insulin requirements. The mass of the insulin producing cells and their location are not known. The possibility to study the mass of insulin producing cells is of importance when developing new treatment regimes, in order to evaluate their efficacy on this parameter.

The researchers in this study are aiming to develop methods to measure the mass of insulin producing cells. A method (positron emission tomography, PET) previously used for the diagnosis of tumors of insulin producing cells may also be used to measure the amount of insulin producing cells in patients with type I diabetes. They plan to evaluate participants with type 1 diabetes that have undergone islet transplantation, to evaluate if PET can be used to measure the beta cell mass after islet transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes

NCT02967354

Type2 Diabetes

COMPLETED NA

Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET

NCT01185119

Healthy

COMPLETED PHASE2/PHASE3

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

NCT01825148

Type 1 Diabetes

COMPLETED

Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

NCT02533219

Hyperinsulinemic Hypoglycemia, Persistent Congenital Hyperinsulinism Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)

NO_LONGER_AVAILABLE

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

NCT01916148

Congenital Hyperinsulinism (CHI) Beckwith-Wiedemann Syndrome Insulinoma

AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positron-Emission Tomography

Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm

Intervention Type PROCEDURE

11C-5-HTP

150-400 MBq \[11C\]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.

Intervention Type BIOLOGICAL

Magnetic Resonance Imaging

Analysis will focus on adipose tissue distribution and composition in the liver.

Intervention Type PROCEDURE

Mixed-Meal Tolerance Test (MMTT)

Intervention Type PROCEDURE

Continuous Glucose Monitoring System® (CGMS)

CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).

Intervention Type PROCEDURE

Glomerular Filtration Rate Testing

Intervention Type PROCEDURE

Blood draw

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Positron Emission Tomography (PET) Imaging PET Scan MRI Scans

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must meet all of the following criteria to be considered eligible for participation in the study:

1. Subjects who are able to provide written informed consent and comply with the procedures of the study protocol.
2. Patient that has received an islet transplant in or outside the CIT01 trial (post primary endpoint).

Exclusion Criteria

Subjects who meet any of these criteria are not eligible for participation in the study:

1. For female subjects: Positive serum pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures at the time of PET scan +/- 2 weeks.
2. Known history of severe co-existing cardiac disease, characterized by any one of the following conditions:

1. Recent myocardial infarction (within past 6 months).
2. Evidence of ischemia on functional cardiac exam within the last year.
3. Left ventricular ejection fraction \<30%.
3. Persistent elevation of liver function tests at the time of study entry. Persistent Aspartate Aminotransferase (serum glutamic-oxaloacetic transaminase), Alanine Aminotransferase (serum glutamate pyruvate transaminase), Alkaline phosphatase or total bilirubin, with values \>1.5 times normal upper limits will exclude a patient.
4. Treatment with any anti-diabetic medication, other than insulin, within 4 weeks of enrollment.
5. Use of any investigational agents within 4 weeks of enrollment.
6. Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.

Eligible Sex

ALL

Accepts Healthy Volunteers

No